TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01575873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection once every 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for risendronate
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risendronate
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for denosumab
Description: Administered by subcutaneous injection once every 6 months
Study: NCT00706654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole depot 300 or 400 mg
Description: Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole 10-30 mg orally
Description: Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
Study: NCT00814593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lymphokine-activated killer cells
Description: Instilled into the tumor bed cavity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polifeprosan 20 with carmustine implant
Description: Intracranial placement
Study: NCT00287521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-37807 Ophthalmic Suspension, 1.0%
Description: One drop in the study eye(s) once daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost, 0.005% (Xalatan)
Description: One drop in the study eye(s) once daily for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AL-37807 Vehicle
Description: One drop in the study eye(s) once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
Description: One drop in the study eye(s) once daily for 28 days
Study: NCT03934840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 20 mg/m2 Q 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 4 Q21 Days x 6 cycles with ADT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: 1000 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg PO daily on chemotherapy completion
Study: NCT02697591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
Study: NCT06188325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: Pharmaceutical form:Capsule-Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: Pharmaceutical form:Capsule-Route of administration:Oral
Study: NCT00706654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole depot 25 or 50 mg
Description: Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo depot
Description: Placebo depot was supplied in lyophilized vials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Placebo tablets were identical in appearance to the aripiprazole tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Placebo tablets were identical in appearance to the aripiprazole tablets.
Study: NCT01139853

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube
Description: Insertion of a 10 French Nasogastric tube prior to surgery
Study: NCT00532870

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic
Study: NCT03952442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized nutrition education
Description: Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine nutrition education
Description: Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
Study: NCT02445651

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Intravenous and Oral n-acetyl cysteine
Study: NCT00826332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transabdominal ultrasound
Description: transabdominal ultrasound

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound
Description: transvaginal ultrasound
Study: NCT03366532

Intervention type: OTHER
Intervention: Dietary assessments
Description: We use food frequency questionnaires to collect and update intake of foods and nutrients in observational studies. No intervention is involved.

Intervention type: OTHER
Intervention: Dietary assessments
Description: We use food frequency questionnaires to collect and update intake of foods and nutrients in observational studies. No intervention is involved.

Intervention type: OTHER
Intervention: Dietary assessments
Description: We use food frequency questionnaires to collect and update intake of foods and nutrients in observational studies. No intervention is involved.
Study: NCT03428906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasally administrated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intranasally administrated
Study: NCT02649205

Intervention type: OTHER
Intervention: Observational study: Supplemented protein-restricted diet
Description: Observational study: Supplemented protein-restricted diet
Study: NCT01001390

Intervention type: DEVICE
Group type: OTHER
Intervention: AFO Device
Description: Ankle Foot Orthoses impact on net oxygen consumption.

Intervention type: DEVICE
Group type: OTHER
Intervention: AFO Device
Description: Ankle Foot Orthoses impact on net oxygen consumption.
Study: NCT03315013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLATE II
Description: The SLATE II algorithm is a series of questions and procedures that allow a study clinician to determine if antiretroviral therapy for HIV can be started immediately (same-day) or if additional care or services are needed before ART initiation.
Study: NCT02893189

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Infusion of modified CAR19 T-cells (4G7-CARD T-cells)
Description: The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.
Study: NCT02713399

Intervention type: DEVICE
Intervention: Optical Coherence Tomography

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Study: NCT01906697

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: middle turbinate Radio Frequency (RF) turbinoplasty
Description: middle turbinate Radio Frequency (RF) turbinoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: middle turbinate resection
Description: middle turbinate resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: middle turbinate medialization
Description: middle turbinate medialization
Study: NCT02370251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB \<2 mg/dL) occurs.
Study: NCT04560647

Intervention type: OTHER
Intervention: No intervention - Psoriasis Subject
Description: Not currently treated plaque psoriasis patients

Intervention type: OTHER
Intervention: No intervention - Control Subject
Description: Control subjects without plaque psoriasis and no family history of psoriasis
Study: NCT00708318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: i.v. fentanyl and AeroLEF
Description: Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN.
Study: NCT01934751

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Intervention (DI)
Description: Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed Intervention (DI)
Description: Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.

Intervention type: OTHER
Group type: OTHER
Intervention: Rapid Intervention (RI)
Description: Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.

Intervention type: OTHER
Group type: OTHER
Intervention: Rapid Intervention (RI)
Description: Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
Study: NCT02116569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.
Study: NCT00196352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets
Description: 1 tablet daily
Study: NCT01803581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: X92001327

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RID shampoo
Study: NCT03470636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartLight X3
Description: Pulmonary vein isolation
Study: NCT03620097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EuPoly-3 DHA Infant
Description: Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
Study: NCT00129753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath-1H)
Description: Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
Study: NCT02521714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study: NCT02181153

Intervention type: OTHER
Group type: OTHER
Intervention: sample blood and fecal collection
Description: Blood and fecal samples will be collected at the day of enrolment

Intervention type: OTHER
Group type: OTHER
Intervention: sample blood and fecal collection
Description: Blood and fecal samples will be collected at the day of enrolment
Study: NCT00867295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin Sodium
Description: cefazolin Sodium 1g i.v. before operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02638103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
Study: NCT01358331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: Administered orally twice daily for 28 days for each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: Administered orally twice daily for 28 days for each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: Administered orally twice daily for 28 days for each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: Administered orally twice daily for 28 days for each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: Administered orally twice daily for 28 days for each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8353
Description: Administered orally twice daily for 28 days for each cycle
Study: NCT01121705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg Interferon alpha2b + Ribavirin
Description: B 1 I or II: Experimental~variable duration of treatment group according with RVR. In case of RVR present patients will be treated for 12 weeks. Patients without RVR will be treated for 24 (B1I) or 36 (B1II)weeks: different duration of treatment for patients without RVR
Study: NCT04149431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Derinat
Description: desoxyribonucleate sodium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Derinat
Description: desoxyribonucleate sodium
Study: NCT02258906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT05762809

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tampa Scale of Kinesiophobia (TSK-17)
Description: The Tampa Scale of Kinesiophobia (TSK-17) was developed as a self-reported checklist to measure fear of pain during movement and fear of reinjury. The TSK-17 consists of 17 questions. Standardized answer options are given as a 4-point Likert scale, and each question is assigned a score from 1 to 4. A normalized score between 17 and 68 points is calculated. A score of 37 or over indicates kinesiophobia.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Knee injury and Osteoarthritis Outcome Score (KOOS)
Description: The KOOS consists of five subscales - Symptoms (S), Pain (P), Functional activities of daily living (ADL), Sport and Recreation Function (Sport/Rec) and Knee-Related Quality of life (QOL) - and total KOOS Outcome (O) scores. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oxford Knee Score (OKS) scoring
Description: OKS consists of 12 questions. Standardized answer options are provided (5 Likert boxes), and each question is assigned a score from 0 to 4. A score of 40-48 indicates no symptoms or satisfactory joint function, 30-39 moderate knee arthritis, 20-29 moderate to severe knee arthritis, and 0-19 severe knee arthritis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quadriceps and hamstring muscle isokinetic strength
Description: Quadriceps and hamstring muscle strength at 60˚/s and 180˚/s were measured with an isokinetic dynamometer. For 180˚/s, five trial and fifteen testing repetitions were used, and for 60˚/s, three trial and three testing repetitions were used. The resting time between trial and testing was two minutes, between different speeds one minute, and between legs two minutes. The maximum peak torques were used in the statistical analysis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single-leg hop test
Description: The single-leg hop test (SLHT) for distance was used for lower limb functional testing. The test started with the participant standing on one leg, toes behind a marked line, and hands on hips throughout to avoid aiding the jump by swinging the arms. The participant was instructed to jump as far as possible and land on the same leg without losing balance. If the patient made contact with the ground with the contralateral limb, lost balance, or made additional hops after landing, the distance was not measured and the jump void. The distance was measured from the starting line to the heel of the leg being tested. For both legs, three trials and three jumps for maximal effort were allowed. The longest distance for both the left leg and the right leg were used in the statistical analysis.